Kai Breuhahn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3574409/publications.pdf

Version: 2024-02-01

89 papers	4,496 citations	94269 37 h-index	106150 65 g-index
92 all docs	92 docs citations	92 times ranked	7867 citing authors

#	Article	IF	Citations
1	Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology, 2013, 144, 1530-1542.e12.	0.6	278
2	Curcumin effectively inhibits oncogenic NF-ÎºB signaling and restrains stemness features in liver cancer. Journal of Hepatology, 2015, 63, 661-669.	1.8	237
3	Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology, 2013, 58, 1703-1712.	3.6	208
4	Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 2014, 4, 730-743.	7.7	165
5	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology, 2014, 59, 1900-1911.	3.6	155
6	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 7059-7066.	0.4	151
7	Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002, 36, 885-894.	3.6	143
8	Keratinocyte-Derived Granulocyte-Macrophage Colony Stimulating Factor Accelerates Wound Healing: Stimulation of Keratinocyte Proliferation, Granulation Tissue Formation, and Vascularization. Journal of Investigative Dermatology, 2001, 117, 1382-1390.	0.3	142
9	Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Modern Pathology, 2010, 23, 480-492.	2.9	131
10	S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology, 2009, 50, 1251-1262.	3.6	129
11	Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. Developmental Biology, 2012, 367, 187-196.	0.9	126
12	Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression. Cancer Research, 2004, 64, 6058-6064.	0.4	119
13	Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology, 2017, 152, 2037-2051.e22.	0.6	118
14	Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood, 2013, 122, 684-693.	0.6	109
15	Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. Journal of Pathology, 2003, 201, 250-259.	2.1	107
16	Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology, 2007, 46, 759-768.	3.6	103
17	Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology, 2008, 48, 146-156.	3.6	100
18	Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology, 2014, 59, 544-554.	3.6	97

#	Article	IF	Citations
19	Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology, 2009, 50, 1130-1139.	3.6	92
20	Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2009, 69, 2234-2243.	0.4	85
21	Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 2004, 25, 1193-1199.	1.3	75
22	Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1690.	1.4	67
23	Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients. Molecular Cancer Research, 2018, 16, 390-402.	1.5	63
24	Down-regulation of tumor suppressor a kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology, 2010, 52, 2023-2033.	3.6	61
25	Comparative Analysis of TGF-Î²/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2013, 8, e72252.	1.1	59
26	Nuclear Pore Component Nup98 Is a Potential Tumor Suppressor and Regulates Posttranscriptional Expression of Select p53 Target Genes. Molecular Cell, 2012, 48, 799-810.	4.5	57
27	Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells. Journal of Hepatology, 2011, 55, 1049-1057.	1.8	52
28	PI3K/AKT/mTORâ€dependent stabilization of oncogenic farâ€upstream element binding proteins in hepatocellular carcinoma cells. Hepatology, 2016, 63, 813-826.	3.6	52
29	Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approaches. Hepatology, 2011, 53, 2112-2121.	3.6	49
30	Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilinâ€2 expression in periâ€tumourous liver correlates with increased survival. Liver International, 2013, 33, 1428-1440.	1.9	49
31	Molecular pathogenesis of human hepatocellular carcinoma. Advances in Cancer Research, 2002, 86, 67-112.	1.9	48
32	Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology, 2018, 67, 1842-1856.	3.6	48
33	FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genetics, 2017, 13, e1007097.	1.5	48
34	YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene, 2019, 38, 5541-5550.	2.6	45
35	The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. Journal of Clinical Investigation, 2010, 120, 3820-3833.	3.9	45
36	Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology, 2014, 60, 1241-1250.	3.6	39

#	Article	IF	Citations
37	The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. OncoImmunology, 2016, 5, e1116674.	2.1	39
38	TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Letters, 2020, 473, 164-175.	3.2	39
39	Concomitant expression of far upstream element (<scp>FUSE</scp>) binding protein (<scp>FBP</scp>) interacting repressor (<scp>FIR</scp>) and its splice variants induce migration and invasion of nonâ€small cell lung cancer (<scp>NSCLC</scp>) cells. Journal of Pathology, 2015, 237, 390-401.	2.1	32
40	YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. Cancer Research, 2020, 80, 5502-5514.	0.4	31
41	Factors of transforming growth factor ? signalling are co-regulated in human hepatocellular carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 589-596.	1.4	29
42	Prosurvival function of the cellular apoptosis susceptibility/importin-Î±1 transport cycle is repressed by p53 in liver cancer. Hepatology, 2014, 60, 884-895.	3.6	29
43	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukinâ€6 signaling in hepatocellular carcinoma. Hepatology, 2016, 64, 828-842.	3.6	29
44	An individual-based model for collective cancer cell migration explains speed dynamics and phenotype variability in response to growth factors. Npj Systems Biology and Applications, 2017, 3, 5.	1.4	29
45	Nucleoporin Nup155 is part of the p53 network in liver cancer. Nature Communications, 2019, 10, 2147.	5.8	29
46	Karyopherin Î±2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell Communication and Signaling, 2019, 17, 159.	2.7	29
47	The designer cytokine hyper-IL-6 mediates growth inhibition and GMâ€“CSF-dependent rejection of B16 melanoma cells. Oncogene, 2001, 20, 972-979.	2.6	27
48	SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6, 2222-2234.	0.8	27
49	Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal of Pathology, 2017, 187, 228-235.	1.9	26
50	Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver International, 2006, 26, 604-612.	1.9	23
51	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 2013, 13, 532.	1.1	23
52	Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatology Research, 2006, 34, 50-56.	1.8	22
53	Nuclear accumulation of seven in absentia homologueâ€2 supports motility and proliferation of liver cancer cells. International Journal of Cancer, 2012, 131, 2016-2026.	2.3	21
54	Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Communication and Signaling, 2020, 18, 166.	2.7	21

#	Article	IF	Citations
55	Transcriptional regulators in hepatocarcinogenesis â€“ Key integrators of malignant transformation. Journal of Hepatology, 2012, 57, 186-195.	1.8	20
56	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. Gastroenterology, 2019, 156, 1190-1205.e14.	0.6	19
57	Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathology and Oncology Research, 2007, 13, 84-90.	0.9	18
58	A dual role for hepatocyte-intrinsic canonical NF-ÎºB signalingÂinÂvirus control. Journal of Hepatology, 2020, 72, 960-975.	1.8	18
59	Cellular apoptosis susceptibility (CAS) is linked to integrin Î²1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget, 2016, 7, 22883-22892.	0.8	18
60	AP-1-Controlled Hepatocyte Growth Factor Activation Promotes Keratinocyte Migration via CEACAM1 and Urokinase Plasminogen Activator/Urokinase Plasminogen Receptor. Journal of Investigative Dermatology, 2009, 129, 1140-1148.	0.3	17
61	YAPâ€induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver International, 2021, 41, 3011-3023.	1.9	17
62	Stathmin Regulates Keratinocyte Proliferation and Migration during Cutaneous Regeneration. PLoS ONE, 2013, 8, e75075.	1.1	16
63	TTCA: an R package for the identification of differentially expressed genes in time course microarray data. BMC Bioinformatics, 2017, 18, 33.	1.2	16
64	A20/TNFAIP3 Discriminates Tumor Necrosis Factor (TNF)-Induced NF-ÎºB from JNK Pathway Activation in Hepatocytes. Frontiers in Physiology, 2017, 8, 610.	1.3	16
65	Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma. Cancer Research, 2016, 76, 5550-5561.	0.4	15
66	Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut, 2021, , gutjnl-2021-325405.	6.1	15
67	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079.	1.1	14
68	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Frontiers in Physiology, 2018, 9, 1918.	1.3	12
69	Nuclear Expression of the Deubiquitinase CYLD Is Associated with Improved Survival in Human Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e110591.	1.1	12
70	Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation. International Journal of Oncology, 2016, 48, 1679-1687.	1.4	11
71	Quantitative Analysis of Gene Expression Relative to 18S rRNA in Carcinoma Samples Using the LightCyclerÂ® Instrument and a SYBR GreenI-based Assay: Determining FAT10 mRNA Levels in Hepatocellular Carcinoma. Methods in Molecular Biology, 2008, 429, 59-72.	0.4	11
72	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	1.7	11

#	Article	IF	Citations
73	A Systems Biology Study on NFÎºB Signaling in Primary Mouse Hepatocytes. Frontiers in Physiology, 2012, 3, 466.	1.3	9
74	Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells. Oral and Maxillofacial Surgery, 2010, 14, 53-57.	0.6	6
75	MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell disseminationâ€"what we learned from microRNA-494. Hepatobiliary Surgery and Nutrition, 2016, 5, 372-376.	0.7	6
76	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yesâ€Associated Protein 1 Activation and Transient Expansion of Stemâ€Like Cancer Cells. Hepatology Communications, 2022, 6, 1140-1156.	2.0	6
77	HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1. Cancers, 2022, 14, 459.	1.7	6
78	LINC00152 Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma. Cells, 2022, 11, 1528.	1.8	6
79	The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment. Current Cancer Therapy Reviews, 2006, 2, 157-167.	0.2	5
80	A Cellular View of Nf2 in Liver Homeostasis and Tumorigenesis. Developmental Cell, 2010, 19, 363-364.	3.1	5
81	Directed random walks and constraint programming reveal active pathways in hepatocyte growth factor signaling. FEBS Journal, 2016, 283, 350-360.	2.2	5
82	Endothelial plasticity governs the siteâ€specific leukocyte recruitment in hepatocellular cancer. International Journal of Cancer, 2013, 133, 2372-2382.	2.3	4
83	Molecular Pathology of Liver Tumors. , 2013, , 43-63.		3
84	Quantitative estimation of tumor cellularity based on histology data. , 2016, , .		1
85	Implementation of systems theory in liver cancer research. Hepatic Oncology, 2015, 2, 9-11.	4.2	0
86	Tumor microvasculature in lung cancer and diffusion-weighted MRI: Preliminary results. , 2016, , .		0
87	Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Frontiers in Physiology, 2019, 10, 1438.	1.3	0
88	Non-canonical NF-ÎºB signaling induces proliferation in primary liver cancer. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
89	Direct interaction of the oncogenes YAP and TAZ with the transcription factor HNF1B in hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0